Research Publications

Research Publications


Atherosclerosis/Metabolic Syndrome

Zhao Y., Chen YQ., Bonacci, T.M., Bredt D.S., Li S., Bensch, W.R., Moller, D.E., Kowala, M., Konrad, R.J., Cao, G. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. Journal of Biological Chemistry (2008) Mar 28;283(13): 8258-65. 


Konicek, B.W., Dumstorf, C.A., Graff, J.R. Targeting the eIF4F translation initiation complex for cancer therapy.  Cell Cycle (2008) Aug 15; 7(16): 2466-71

Low, J., Huang, S., Blosser, W., Dowless, M., and Stancato L.   High Content Imaging Characterization of Cell Cycle Therapeutics Through In Vitro and In Vivo Subpopulation Analysis.  Molecular Cancer Therapeutics (2008) Aug;7(8):2455-63

Integrative Biology

Saxena, C., Zhen E., Higgs, RE And Hale, JE.  An immuno-chemo-proteomics method for drug target deconvolution.  Journal of Proteome Research (2008) 7: 3490


Ardayfio, P., Benvenga, M., Chaney, S., Love, P., Catlow, J., Swanson, S., Marek G.  
The 5-hydroxytryptamine2A receptor antagonist M100907 attenuates impulsivity after both drug induced disruption (dizocilpine) and enhancement (antidepressant drugs) of  Differential-Reinforcement-of-Low Rate 72-s behavior in the rat.  Journal of Pharmacology and Experimental Therapeutics (2008) 327, 891-7

Fell, M.J., Svensson, K.A., Johnson, B.G., Schoepp, D.D.,.  Evidence for mGlu2 and not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. Journal of Pharmacology and Experimental Therapeutics (2008) 326(1):209-17

Kato, A.S., Siuda, E.R., Nisenbaum, E.S., Bredt, D.S.  AMPA receptor subunit-specific regulation by a distinct family of Type II TARPs.  Neuron (2008) 59: 986-996

Zhao, L,  Lin. S., Bales K., Gelfanova, V., Koger, D., Delong, C., Hale, J., Liu, F., Hunter, J., Paul, S. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism.  Journal of Neuroscience (2009)  29(11):3603–3612


Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability or any other legally protected status.